Haemonetics Corporation (HAE) - Q3 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended December 28, 2024 (Q3 of Fiscal 2025). Haemonetics is a global healthcare company operating in three segments: Plasma, Blood Center, and Hospital. The period was marked by significant strategic activity, including the acquisition of Attune Medical, the divestiture of the Whole Blood product line, and major capital structure refinancing.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Net Revenues | $348.5 million | $336.3 million | $1,030.2 million | $965.8 million |
| Gross Profit | $193.5 million | $177.9 million | $555.9 million | $515.6 million |
| Gross Margin | 55.5% | 52.9% | 54.0% | 53.4% |
| Operating Income | $59.0 million | $46.0 million | $150.5 million | $134.9 million |
| Operating Margin | 16.9% | 13.7% | 14.6% | 14.0% |
| Net Income | $37.5 million | $31.2 million | $109.7 million | $97.2 million |
| Diluted EPS | $0.74 | $0.61 | $2.14 | $1.89 |
| Cash & Equivalents | $320.8 million | $178.8 million (FY24 End) | N/A | |
| Long-Term Debt | $1,219.8 million | $797.6 million (FY24 End) | N/A | |
| Working Capital | $752.6 million | $468.5 million (FY24 End) | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 3.7% QoQ and 6.7% YTD, driven primarily by the Hospital segment (+23.9% QoQ), which benefited from recent acquisitions (OpSens, Attune Medical) and growth in Interventional Technologies. This offset declines in the Plasma (-9.1%) and Blood Center (-2.8%) segments.
- Profitability Expansion: Operating income rose 28.4% QoQ due to operating leverage, reduced performance-based compensation, and lower transaction costs, partially offset by higher amortization of acquired intangibles ($12.2M vs $6.9M prior year).
- Debt Restructuring: The company issued $700 million in 2.5% Convertible Senior Notes due 2029. Proceeds were used to repay the revolving credit facility, repurchase $200 million of 2026 Notes (generating a $12.6M net gain), and fund capped call transactions. Total long-term debt increased significantly to $1.22 billion.
- Divestiture: The Whole Blood product line (Blood Center segment) was sold to GVS, S.p.A. for up to $67.8 million. Assets were reclassified as "held for sale" at period end.
- Share Repurchases: Completed a $75.0 million Accelerated Share Repurchase (ASR) in October 2024, acquiring 1.0 million shares. $150.0 million remains authorized under the current program.
Guidance, Outlook, and Risks
- Outlook: Management views Plasma and Hospital segments as having growth potential, while Blood Center faces challenging markets requiring cost management and scope reduction. The company anticipates approximately $100 million in sales to CSL Plasma in Fiscal 2025.
- Restructuring: The "Operational Excellence Program" expects aggregate charges of ~$85 million by the end of Fiscal 2025. $83.0 million has been incurred to date. Portfolio rationalization initiatives continue to incur costs related to ending the life of the ClotPro analyzer and Whole Blood products.
- Risks & Contingencies:
- Legal: A class action settlement regarding biometric data (BIPA) was paid ($8.7M) in Q1 2025. A new patent infringement lawsuit was filed by Philips against OpSens in Q4 2024; the company plans to vigorously defend.
- Customer Concentration: Plasma sales are concentrated with large biopharmaceutical customers, including CSL Plasma, whose non-exclusive agreement expires in December 2025.
- Foreign Exchange: 26.1% of sales are generated outside the U.S. (primarily Yen, Euro, Yuan). A strengthening U.S. Dollar adversely impacts results.
Investor Verification Checklist
- Acquisition Integration: Verify the revenue contribution and margin impact of the Attune Medical and OpSens acquisitions in upcoming quarters.
- Debt Service: Monitor interest expense trends related to the new 2029 Notes and the effective interest rate on the term loan (currently 6.1%).
- Plasma Segment: Track the impact of the CSL Plasma contract expiration in late 2025 on future revenue guidance.
- Divestiture Completion: Confirm the final cash consideration received from the GVS sale of the Whole Blood line (up to $22.5M contingent).
- Restructuring Costs: Review the remaining $2.0 million expected under the Operational Excellence Program and the timeline for completion.